Form 4: NeoGenomics CAO Aunan Exercises RSUs, Adjusts Holdings
Insider Transaction Report
NeoGenomics Chief Accounting Officer Greg D. Aunan reported the exercise of restricted stock units and subsequent tax-related share disposition, adjusting his direct beneficial ownership.
Summary
- Greg D. Aunan, Chief Accounting Officer of NeoGenomics Inc. (NEO), reported transactions on February 21, 2026.
- Acquired 6,323 shares of common stock through the conversion of restricted stock units (RSUs) at a price of $0.
- Disposed of 1,875 shares of common stock to satisfy tax withholding obligations related to the RSU vesting, also at a price of $0.
- Following these transactions, Mr. Aunan directly beneficially owns 22,027 shares of common stock.
- He also holds 12,648 restricted stock units and 86,803 stock options across various grants.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing a routine insider transaction related to equity compensation vesting and tax withholding, which is a standard practice and does not indicate a change in company fundamentals or outlook.
Positives
- Chief Accounting Officer Greg D. Aunan's restricted stock units vested, indicating continued long-term incentive alignment with company performance.
Negatives
- 1,875 shares were disposed of to cover tax withholding obligations, which is a common practice upon RSU vesting and reduces the direct share count.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider transactions, particularly those related to equity compensation vesting and tax withholding, are routine and generally do not reflect a change in management's outlook on the company's prospects. They are a standard part of executive compensation packages in the biotechnology and diagnostics industry.
Comparison to Industry Standards
- This is a standard Form 4 filing for an insider transaction related to equity compensation.
- Such transactions are common across all publicly traded companies, including peers in the diagnostics sector like Guardant Health (GH) or Exact Sciences (EXAS), where executives regularly report vesting and exercise of stock awards.
- The specific numbers reflect Mr. Aunan's compensation package at NeoGenomics and are consistent with typical executive equity compensation structures in the industry.
Stakeholder Impact
- Shareholders: Minimal direct impact as these are routine compensation-related transactions and do not signal a change in company strategy or performance.
- Employees: No direct impact mentioned beyond the reporting person's compensation.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Grant date for 28,662 stock options to Mr. Aunan, vesting ratably over four years. |
| 05/02/2024 | Grant date for 26,978 stock options and 16,117 restricted stock units to Mr. Aunan, both vesting ratably over three years. |
| 02/21/2025 | Grant date for 18,971 restricted stock units and 31,163 stock options to Mr. Aunan, both vesting ratably over three years. |
| 02/21/2026 | Transaction date for the acquisition of common stock from RSU conversion and disposition for tax withholding. |
| 02/24/2026 | Filing date of the Form 4. |
| 05/01/2030 | Expiration date for 28,662 stock options granted on May 1, 2023. |
| 05/02/2034 | Expiration date for 26,978 stock options granted on May 2, 2024. |
| 02/21/2035 | Expiration date for 31,163 stock options granted on February 21, 2025. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to equity compensation vesting and tax withholding for the Chief Accounting Officer. Such transactions are standard and do not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for buying or selling.
Keywords
NEOGENOMICS, NEO, Greg D. Aunan, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Chief Accounting Officer, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.